Literature DB >> 34028353

Introduction to the EQIPD quality system.

Anton Bespalov1, René Bernard2, Anja Gilis3, Björn Gerlach4, Javier Guillen5, Vincent Castagne6, Isabel Lefevre7, Fiona Ducrey8, Lee Monk9, Sandrine Bongiovanni10, Bruce Altevogt11, Maria Arroyo Araujo12, Lior Bikovski13, Natasja de Bruin14, Esmeralda Castaños-Vélez2, Alexander Dityatev15, Christoph H Emmerich16, Raafat Fares17, Chantelle Ferland-Beckham18, Christelle Froger-Colléaux6, Valerie Gailus-Durner19, Sabine M Hölter20, Martine Cj Hofmann14, Patricia Kabitzke21, Martien J H Kas12, Claudia Kurreck2, Paul Moser22, Malgorzata Pietraszek16, Piotr Popik23, Heidrun Potschka24, Ernesto Prado Montes de Oca25, Leonardo Restivo26, Gernot Riedel27, Merel Ritskes-Hoitinga28, Janko Samardzic29, Michael Schunn30, Claudia Stöger31, Vootele Voikar32, Jan Vollert33, Kimberley E Wever28, Kathleen Wuyts34, Malcolm R MacLeod35, Ulrich Dirnagl2, Thomas Steckler3.   

Abstract

While high risk of failure is an inherent part of developing innovative therapies, it can be reduced by adherence to evidence-based rigorous research practices. Numerous analyses conducted to date have clearly identified measures that need to be taken to improve research rigor. Supported through the European Union's Innovative Medicines Initiative, the EQIPD consortium has developed a novel preclinical research quality system that can be applied in both public and private sectors and is free for anyone to use. The EQIPD Quality System was designed to be suited to boost innovation by ensuring the generation of robust and reliable preclinical data while being lean, effective and not becoming a burden that could negatively impact the freedom to explore scientific questions. EQIPD defines research quality as the extent to which research data are fit for their intended use. Fitness, in this context, is defined by the stakeholders, who are the scientists directly involved in the research, but also their funders, sponsors, publishers, research tool manufacturers and collaboration partners such as peers in a multi-site research project. The essence of the EQIPD Quality System is the set of 18 core requirements that can be addressed flexibly, according to user-specific needs and following a user-defined trajectory. The EQIPD Quality System proposes guidance on expectations for quality-related measures, defines criteria for adequate processes (i.e., performance standards) and provides examples of how such measures can be developed and implemented. However, it does not prescribe any pre-determined solutions. EQIPD has also developed tools (for optional use) to support users in implementing the system and assessment services for those research units that successfully implement the quality system and seek formal accreditation. Building upon the feedback from users and continuous improvement, a sustainable EQIPD Quality System will ultimately serve the entire community of scientists conducting non-regulated preclinical research, by helping them generate reliable data that are fit for their intended use.
© 2021, Bespalov et al.

Entities:  

Keywords:  neuroscience

Year:  2021        PMID: 34028353     DOI: 10.7554/eLife.63294

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  9 in total

1.  The Roles of Long-Term Hyperhomocysteinemia and Micronutrient Supplementation in the AppNL-G-F Model of Alzheimer's Disease.

Authors:  Hendrik Nieraad; Natasja de Bruin; Olga Arne; Martine C J Hofmann; Nina Pannwitz; Eduard Resch; Sonja Luckhardt; Ann-Kathrin Schneider; Sandra Trautmann; Yannick Schreiber; Robert Gurke; Michael J Parnham; Uwe Till; Gerd Geisslinger
Journal:  Front Aging Neurosci       Date:  2022-04-26       Impact factor: 5.702

2.  Towards best practices in research: Role of academic core facilities.

Authors:  Leonardo Restivo; Björn Gerlach; Michael Tsoory; Lior Bikovski; Sylvia Badurek; Claudia Pitzer; Isabelle C Kos-Braun; Anne-Laure Mj Mausset-Bonnefont; Jonathan Ward; Michael Schunn; Lucas Pjj Noldus; Anton Bespalov; Vootele Voikar
Journal:  EMBO Rep       Date:  2021-11-04       Impact factor: 8.807

3.  Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.

Authors:  Natasja de Bruin; Ann-Kathrin Schneider; Philipp Reus; Sonja Talmon; Sandra Ciesek; Denisa Bojkova; Jindrich Cinatl; Imran Lodhi; Bruce Charlesworth; Simon Sinclair; Graham Pennick; William F Laughey; Philip Gribbon; Aimo Kannt; Susanne Schiffmann
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

Review 4.  Importing genetically altered animals: ensuring quality.

Authors:  M-C Birling; M D Fray; P Kasparek; J Kopkanova; M Massimi; R Matteoni; L Montoliu; L M J Nutter; M Raspa; J Rozman; E J Ryder; F Scavizzi; V Voikar; S Wells; G Pavlovic; L Teboul
Journal:  Mamm Genome       Date:  2021-09-18       Impact factor: 2.957

5.  Improving the reproducibility and integrity of research: what can different stakeholders contribute?

Authors:  Malcolm Macleod
Journal:  BMC Res Notes       Date:  2022-04-25

6.  Introducing quality measures in an academic research consortium: Lessons and recommendation from implementing an ad hoc quality management system for organ model research: Lessons and recommendation from implementing an ad hoc quality management system for organ model research.

Authors:  Maren Hülsemann; Janine Wiebach; Natascha Ingrid Drude; Silke Kniffert; Laura Behm; Katja Hönzke; Morris Baumgardt; Stefan Hippenstiel; Andreas C Hocke; Ulrich Dirnagl; Ulf Tölch
Journal:  EMBO Rep       Date:  2022-07-25       Impact factor: 9.071

7.  SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain.

Authors:  Saskia Wedel; Praveen Mathoor; Oliver Rauh; Tim Heymann; Cosmin I Ciotu; Dominik C Fuhrmann; Michael J M Fischer; Andreas Weigert; Natasja de Bruin; Felix Hausch; Gerd Geisslinger; Marco Sisignano
Journal:  J Neuroinflammation       Date:  2022-10-10       Impact factor: 9.587

Review 8.  Issues in the design, analysis, and application of rodent developmental neurotoxicology studies.

Authors:  Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2021-07-10       Impact factor: 4.071

Review 9.  Improving target assessment in biomedical research: the GOT-IT recommendations.

Authors:  Christoph H Emmerich; Lorena Martinez Gamboa; Martine C J Hofmann; Marc Bonin-Andresen; Olga Arbach; Pascal Schendel; Björn Gerlach; Katja Hempel; Anton Bespalov; Ulrich Dirnagl; Michael J Parnham
Journal:  Nat Rev Drug Discov       Date:  2020-11-16       Impact factor: 112.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.